GLYATL1 (glycine-N-acyltransferase like 1) is a mitochondrial acyltransferase that catalyzes the conjugation of acyl groups to amino acids, specifically transferring acyl groups to the N-terminus of glutamine using phenylacetyl-CoA as an acyl donor 1. Unlike its paralog GLYAT, which preferentially conjugates benzoyl-CoA to glycine, GLYATL1 functions as an arylacetyl transferase with glutamine-N-acyltransferase activity 1. The enzyme may also participate in detoxification pathways, as in silico and in vitro studies suggest it can form N-isovalerylglycine, potentially playing a role in alleviating symptoms in isovaleric acidemia patients, though with lower affinity than its preferred substrates 2. GLYATL1 demonstrates significant clinical relevance across multiple cancer types. In hepatocellular carcinoma (HCC), GLYATL1 expression is suppressed and associated with poor prognosis, functioning as a tumor suppressor through the PLGLA/miR-324-3p/GLYATL1 axis 3. The gene is included in prognostic models for HCC, kidney renal cell carcinoma, and endometrial cancer, with its expression levels correlating with disease progression and patient outcomes 456. In prostate cancer, GLYATL1 shows overexpression in primary tumors and is regulated by androgen and ETV1 transcription factor 7.